Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)June 24, 2026 8:53 AM
IH Market News Spyre Therapeutics Inc. (NASDAQ:SYRE) shares dropped 13.7% in premarket trading on Wednesday after regulatory filings revealed significant stock sales by company insiders, including a transaction worth nearly $400 million by an investment fund affiliated with members of the board. The disclosures raised concerns among investors about insider sentiment and prompted selling pressure in the stock. Fairmount Fund Exits Common Stock Position According to a Form 4 filing submitted to the U.S. Securities and Exchange Commission, Fairmount Healthcare Fund II L.P. sold 4,684,781 shares of Spyre common stock on June 23 at a price of $85.31 per share. The transaction was valued at approximately $399.7 million and reduced the fund’s common stock ownership to zero shares. Fairmount Healthcare Fund II L.P. is affiliated with directors of Spyre Therapeutics, making the transaction particularly notable for investors monitoring insider activity. Sale Followed Preferred Stock Conversion The share sale occurred after the fund converted 16,667 shares of Series B Preferred Stock into 666,680 shares of common stock. Under the terms of the preferred securities, each Series B Preferred share is convertible into 40 common shares, subject to certain beneficial ownership limitations. The conversion and subsequent sale formed part of the broader reduction in the fund’s exposure to Spyre’s common equity. Board Connections Draw Investor Attention Fairmount Funds Management LLC serves as investment manager for Fairmount Healthcare Fund II L.P. The firm is managed by Peter Harwin and Tomas Kiselak, with Kiselak currently serving as a member of Spyre Therapeutics’ board of directors. Given the board-level connection, investors closely scrutinized the transaction as a potential indicator of insider views regarding valuation or future prospects. Director Also Sells Shares In a separate filing, Spyre director Michael Thomas Henderson disclosed the sale of 20,000 shares on June 22 at a price of $100 per share. The transaction generated proceeds of approximately $2 million. The filing stated that the sale was conducted under a Rule 10b5-1 trading plan that had been adopted on February 6, 2026. Following the transaction, Henderson continued to own 68,606 shares of Spyre common stock. Significant Preferred Share Position Remains Despite the disposal of its common stock holdings, Fairmount Healthcare Fund II L.P. retains a sizeable position through preferred securities. Following the reported transactions, the fund continues to own 346,045 shares of Series A Preferred Stock. Those securities are convertible into 13,841,800 shares of common stock under conversion terms similar to those governing the Series B Preferred Stock and remain subject to beneficial ownership restrictions. Investors React to Insider Activity Large insider transactions often attract investor attention, particularly when they involve board-affiliated shareholders and substantial dollar amounts. While the filings do not indicate the reasons behind the sales, the scale of the transactions contributed to negative sentiment surrounding the stock and weighed on shares in premarket trading. Investors will likely continue monitoring future insider activity and any additional disclosures regarding the remaining preferred share holdings as they assess the implications for Spyre Therapeutics’ shareholder base and stock performance. Spyre Therapeutics stock priceThe post Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE) appeared first on US Editors. Original: Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)

Spyre Therapeutics shares jump after positive ulcerative colitis trial dataApril 13, 2026 10:11 AM
IH Market News
Spyre Therapeutics (NASDAQ:SYRE) shares climbed 25% on Monday after the company reported that its investigational therapy SPY001 achieved its primary endpoint in a Phase 2 study targeting ulcerative colitis.The biotech group released 12-week results from Part A of its SKYLINE trial, showing that SPY001 delivered a statistically significant 9.2-point reduction in the Robarts Histopathology Index. The treatment, an anti-a4ß7 antibody, is being developed for patients with moderate-to-severe ulcerative colitis.Secondary measures were also encouraging, with clinical remission observed in 40% of patients and endoscopic improvement seen in 51%. The Modified Mayo Score fell by 3.7 points from baseline.A total of 43 patients were enrolled in the study. SPY001 demonstrated a safety profile consistent with other drugs in the a4ß7 class. Six participants experienced treatment-emergent adverse events during the induction phase, including one serious event that was not considered related to the drug. Back pain was the most commonly reported side effect, affecting two patients.Enrollment for Part A of the SKYLINE trial has now been completed, and the company has moved on to recruiting patients for Part B. This phase will include three monotherapy arms and three combination cohorts, testing SPY001 alongside additional investigational antibodies, SPY002 and SPY003.Spyre said it expects proof-of-concept data from the remaining Part A cohorts in mid-2026 for SPY002 and in the third quarter of 2026 for SPY003. Readouts from Part B across all cohorts are currently anticipated in 2027.The company is positioning SPY001 as a potential best-in-class anti-a4ß7 therapy, designed with an extended half-life to improve durability and outcomes compared with existing treatments for inflammatory bowel disease.Spyre Therapeutics stock price

Original: Spyre Therapeutics shares jump after positive ulcerative colitis trial data

SYRE up and down but mostly up

SYRE new 52=week high